Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus
Rongxiu Huo,* Xinxiang Huang,* Yang Yang, Jinying Lin Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, the People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, People’s Republic of China*These authors contributed equally to this workC...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-04-01
|
| Series: | Journal of Inflammation Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/potential-use-of-janus-kinase-inhibitors-in-the-treatment-of-systemic--peer-reviewed-fulltext-article-JIR |
| _version_ | 1797848454128467968 |
|---|---|
| author | Huo R Huang X Yang Y Lin J |
| author_facet | Huo R Huang X Yang Y Lin J |
| author_sort | Huo R |
| collection | DOAJ |
| description | Rongxiu Huo,* Xinxiang Huang,* Yang Yang, Jinying Lin Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, the People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jinying Lin, Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, the People’s Hospital of Guangxi Zhuang Autonomous Region, 6 Taoyuan Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, 530016, People’s Republic of China, Email jinyinglin@sina.comAbstract: Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease with unclear pathogenesis. One characteristic of SLE is pro-inflammatory and anti-inflammatory cytokine imbalance. Janus kinase (JAK) is an intracellular non-receptor tyrosine kinase essential for many cytokine signaling pathways. Dysregulation of the JAK/signal transduction and transcriptional activator (STAT) pathway is an important process in SLE pathogenesis. Targeting JAK/STAT proteins can simultaneously block the functions of multiple cytokines. Current SLE treatment with non-specific corticosteroids and immunosuppressants can cause many adverse reactions. Therefore, treatments designed to control specific molecular targets for SLE are desirable. JAK inhibitors (JAKis) are a potential treatment for rheumatic diseases; however, the use of targeted signaling pathways to treat SLE remains a challenge, and its efficacy has not been determined. JAKis have shown positive results in reducing the use of glucocorticoids and/or non-specific immunosuppressants for SLE. JAKis are currently undergoing several clinical trials and expected to be the next stage in the treatment of SLE. Therefore, inhibition of the JAK/STAT pathway through JAKis may improve traditional treatment strategies for SLE.Keywords: systemic lupus erythematosus, Janus kinase, JAK/STAT pathway, JAK inhibitors |
| first_indexed | 2024-04-09T18:27:47Z |
| format | Article |
| id | doaj.art-8be3e328e65e4f0aad0636a1ccab872b |
| institution | Directory Open Access Journal |
| issn | 1178-7031 |
| language | English |
| last_indexed | 2024-04-09T18:27:47Z |
| publishDate | 2023-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Inflammation Research |
| spelling | doaj.art-8be3e328e65e4f0aad0636a1ccab872b2023-04-11T19:05:00ZengDove Medical PressJournal of Inflammation Research1178-70312023-04-01Volume 161471147882858Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus ErythematosusHuo RHuang XYang YLin JRongxiu Huo,* Xinxiang Huang,* Yang Yang, Jinying Lin Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, the People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jinying Lin, Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, the People’s Hospital of Guangxi Zhuang Autonomous Region, 6 Taoyuan Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, 530016, People’s Republic of China, Email jinyinglin@sina.comAbstract: Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease with unclear pathogenesis. One characteristic of SLE is pro-inflammatory and anti-inflammatory cytokine imbalance. Janus kinase (JAK) is an intracellular non-receptor tyrosine kinase essential for many cytokine signaling pathways. Dysregulation of the JAK/signal transduction and transcriptional activator (STAT) pathway is an important process in SLE pathogenesis. Targeting JAK/STAT proteins can simultaneously block the functions of multiple cytokines. Current SLE treatment with non-specific corticosteroids and immunosuppressants can cause many adverse reactions. Therefore, treatments designed to control specific molecular targets for SLE are desirable. JAK inhibitors (JAKis) are a potential treatment for rheumatic diseases; however, the use of targeted signaling pathways to treat SLE remains a challenge, and its efficacy has not been determined. JAKis have shown positive results in reducing the use of glucocorticoids and/or non-specific immunosuppressants for SLE. JAKis are currently undergoing several clinical trials and expected to be the next stage in the treatment of SLE. Therefore, inhibition of the JAK/STAT pathway through JAKis may improve traditional treatment strategies for SLE.Keywords: systemic lupus erythematosus, Janus kinase, JAK/STAT pathway, JAK inhibitorshttps://www.dovepress.com/potential-use-of-janus-kinase-inhibitors-in-the-treatment-of-systemic--peer-reviewed-fulltext-article-JIRsystemic lupus erythematosusjanus kinasejak/stat pathwayjak inhibitors |
| spellingShingle | Huo R Huang X Yang Y Lin J Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus Journal of Inflammation Research systemic lupus erythematosus janus kinase jak/stat pathway jak inhibitors |
| title | Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus |
| title_full | Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus |
| title_fullStr | Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus |
| title_full_unstemmed | Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus |
| title_short | Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus |
| title_sort | potential use of janus kinase inhibitors in the treatment of systemic lupus erythematosus |
| topic | systemic lupus erythematosus janus kinase jak/stat pathway jak inhibitors |
| url | https://www.dovepress.com/potential-use-of-janus-kinase-inhibitors-in-the-treatment-of-systemic--peer-reviewed-fulltext-article-JIR |
| work_keys_str_mv | AT huor potentialuseofjanuskinaseinhibitorsinthetreatmentofsystemiclupuserythematosus AT huangx potentialuseofjanuskinaseinhibitorsinthetreatmentofsystemiclupuserythematosus AT yangy potentialuseofjanuskinaseinhibitorsinthetreatmentofsystemiclupuserythematosus AT linj potentialuseofjanuskinaseinhibitorsinthetreatmentofsystemiclupuserythematosus |